On 15 December 2021 Dr. Ashley Bloomfield wrote to District Health Boards describing the risks of Myocarditis and Pericarditis following vaccination. He estimated that the incidence of cases was 3 per 100,000 vaccinations. We note that this is little different from the expected background rate. Accordingly, Dr. Bloomfield described the risk as ‘serious’ but ‘very rare’.
Dr. Bloomfield described the New Zealand symptomatology as:
- Chest heaviness, discomfort, tightness, or pain
- Difficulty breathing, shortness of breath
- Feeling dizzy, light-headed or faint
- Racing or fluttering heart, or a feeling of ‘skipped beats’
Dr. Bloomfield said that serious complications can be avoided with timely assessment and treatment. He warned against leaving the condition untreated.
Medsafe publishes an Adverse Events Following Immunisation (AEFI) spreadsheet. We have extracted figures for myocarditis rates current to 22 February 2022. This shows that the actual incidence of myocarditis for under 40 year olds is between 4 to 7 times higher than the expected rate per 100,000 vaccinations. Considerably higher than Dr. Bloomfield hoped.
The latest New Zealand figures we report above are broadly confirmed by a recent study (SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents) in Nordic countries and by figures from other countries.
We further note that the New England Journal of Medicine in an editorial has raised concerns about the use of boosters among younger (under 40) age groups.
In a parallel development, a report published by Nature (Increased emergency cardiovascular events among under-40 population in Israel during vaccine rollout and third COVID-19 wave) has found that the incidence of emergency medical call outs for cardiac events is statistically related to Pfizer mRNA vaccination, but not related to Covid infection:
“…the findings raise concerns regarding vaccine-induced undetected severe cardiovascular side-effects and underscore the already established causal relationship between vaccines and myocarditis, a frequent cause of unexpected cardiac arrest in young individuals.”
We want to alert the medical profession to the potential time bomb for New Zealand healthcare that these two findings together raise. There is a real possibility that subclinical or mild cases of myocarditis following Covid vaccination suggested by the symptomatology above (of which CARM has noted tens of thousands of reports) have in fact been missed or insufficiently treated.
It appears that the initial assessment by the Ministry of Health might have underestimated the potential for serious cardiac complications of mRNA vaccination, both short term and long term.
Myocarditis has been diagnosed as a problem following 1, 2, and booster doses of the Pfizer mRNA vaccine. Some medical experts in the USA have suggested recently that the routine administration of diagnostic tests in cases of chest pain etc. might be useful in gauging the seriousness and potential long term effects of following mRNA vaccination. We note troponin tests are inexpensive and can rapidly detect cardiac damage.
We are aware of multiple reports of an increased rate of cardiac events in New Zealand among all age groups, but especially concerning are events for younger people, both male and female. These may be preventable. We are concerned about the lack of availability of up to date centralised data on the current rates of cardiac events in hospital EDs, in the community, and from GPs. At the present time, the public is ill-informed about the levels of risk.
If you are reading this as a medical professional, we suggest that if you are in possession of evidence of increased risks or you are concerned or puzzled in any way by increased caseloads or individual cases, it would be sensible and professionally ethical to speak up now, exchange information within your professional circles, and take appropriate precautionary action.
HatchardReport.com suggests that readers circulate this to doctors.
